Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

business remains solid. We continue to invest in our pipeline while simultaneously generating strong sales, earnings, and cash flow."

The company is updating its guidance for 2008. Total sales guidance is increased to $1.90 - $1.94 billion. This includes CNS franchise sales of $1.02 - $1.04 billion, pain franchise sales of $500 - $520 million, oncology franchise sales of $175 - $185 million, and other product sales of $200 - $210 million. Full year SG&A and R&D guidance is $800 - $815 million and $340 - $355 million, respectively. Adjusted net income guidance for 2008 is $354 - $360 million and basic adjusted income per common share guidance is increased by $0.10 per share to $5.20 - $5.30.

Cephalon is introducing 2009 sales guidance of $2.175 - $2.225 billion. This includes CNS franchise sales of $1.15 - $1.18 billion, pain franchise sales of $535 - $560 million, oncology franchise sales of $265 - $280 million, and other product sales of $180 - $205 million. SG&A and R&D guidance for 2009 are $840 - $860 million and $390 - $410 million, respectively.

The company also is introducing adjusted net income guidance for 2009 of $452 - $459 million. This represents growth of approximately 27 percent over our increased 2008 guidance. Cephalon is introducing 2009 basic adjusted income per common share guidance of $6.50 - $6.60.

Basic adjusted income per common share guidance for both the full-year 2008 and full-year 2009 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's third quarter 2008 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today. To participate in the conference call, dial +1-913-312-9315 and refer to conference code number 8454517. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015  In recognition of World Hemophilia Day, Biogen ... to illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Mercedes-Benz Superdome and Denver,s Coors ... April 17, and coincide with hemophilia community events in a ...
(Date:4/16/2015)... /CNW/ - Bioenterprise Corporation is pleased to announce that it ... Charlottetown , PEI.  Bioenterprise has established a 3-year ... for the commercialization of agricultural technologies and innovations. ... ADAPT.  They have been at the heart of agri-innovation ... Dave Smardon , President & CEO of Bioenterprise ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Mass. , April 16, 2015  EMD ... Merck KGaA, Darmstadt, Germany , ... Vice President, Head of Global Clinical Development.  Dr. ... expertise, including experience in Oncology and Immunology. She ... ability, having served as a Vice President in ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China,announced that ... and Exchange Commission (SEC) that, if declared effective by ... to time, up to $100 million,of its common stock ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ) a ... in the People,s Republic of China,announced that it intends ... March 31, 2008, on Thursday, June 12, 2008., ... Thursday, June,12, 2008 at 9:00 a.m. Eastern Time to ...
... Patients Shipped in the Quarter ... ... BEDFORD, Mass., May 13 Insulet Corporation,(Nasdaq: PODD ), a ... today announced financial results for,the first quarter ended March 31, 2008., ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... has already had dramatic effects on individual species, with ... migration. But, in a new study from the open-access ... Getz show that the impact of climate change on ... by a top predator - the reintroduced gray wolf ...
... A newly discovered mechanism by which an infectious fungus ... virulence, according to Howard Hughes Medical Institute investigators at ... in light following fungal invasion of the human body ... sparks infection, the researchers said. , The discovery in ...
... damage to the heart that can cause congestive ... limited ability of the myocardium to regenerate and ... now document the existence of a previously unrecognized ... therapeutic potency for myocardial tissue regeneration following myocardial ...
Cached Biology News:Gray wolves maintain the food chain in winter 2Light therapy may combat fungal infections, new evidence suggests 2Light therapy may combat fungal infections, new evidence suggests 3
... ELF 97 Cytological Labeling Kit provides a ... detection of cellular targets, including cell-surface receptors ... Labeling Kit contains the patented ELF 97 ... yellow-green precipitate at the site of enzymatic ...
... H 10 O 2 S 2 ... Form: White crystalline powder Assay: greater ... By IR Melting Point: greater than ... less than or equal to 1% ...
... The Fluorescence Test Plate consists of ... format, with Inert Organic Fluorescent Compounds embedded ... be used on BioTeks FLx800 and Synergy ... ideal for GLP compliance while reducing the ...
... excellent performance with isocratic IC methods. ... column heater all standard, this compact, ... stability. The vacuum degas option delivers ... Operate in manual or automated mode ...
Biology Products: